High Mobility Group Box 1 Contributes to the Pathogenesis of Experimental Pulmonary Hypertension via Activation of Toll-like Receptor 4
暂无分享,去创建一个
Ferhaan Ahmad | S. Erzurum | S. Comhair | T. Billiar | R. Shapiro | E. Bauer | P. Bauer | D. Ishizawar | Han Zheng
[1] T. Kanda,et al. Circulating levels of HMGB1 are correlated strongly with MD2 in HIV-infection: Possible implication for TLR4-signalling and chronic immune activation , 2013, Innate immunity.
[2] L. Yazmalar,et al. Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life , 2013, Rheumatology International.
[3] V. Heinemann,et al. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy , 2013, Tumor Biology.
[4] T. Billiar,et al. High Mobility Group Box 1 Inhibits Human Pulmonary Artery Endothelial Cell Migration via a Toll-like Receptor 4- and Interferon Response Factor 3-dependent Mechanism(s)* , 2012, The Journal of Biological Chemistry.
[5] M. Guzmán,et al. Elevated serum levels of high mobility group box 1 (HMGB1) protein in dengue-infected patients are associated with disease symptoms and secondary infection. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[6] Si-young Song,et al. Serum high mobility group box‐1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma , 2012, Cancer science.
[7] H. Naruse,et al. Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction. , 2012, Atherosclerosis.
[8] V. Gangji,et al. Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjögren's syndrome , 2012, Scandinavian journal of rheumatology.
[9] K. Tracey,et al. Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis , 2012, Arthritis Research & Therapy.
[10] S. Erzurum,et al. Complement C3 Deficiency Attenuates Chronic Hypoxia-Induced Pulmonary Hypertension in Mice , 2011, PloS one.
[11] Xin J. Zhou,et al. Early interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4. , 2011, Kidney international.
[12] J. A. Nogueira-Machado,et al. HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation , 2011, Expert opinion on therapeutic targets.
[13] I. Maruyama,et al. The Role Of High Mobility Group Box1 In Monocrotaline-Induced Pulmonary Hypertension In Rats , 2011, ATS 2011.
[14] S. Akira,et al. Pathogen Recognition by the Innate Immune System , 2011, International reviews of immunology.
[15] M. Bianchi,et al. TLR4‐mediated skin carcinogenesis is dependent on immune and radioresistant cells , 2010, The EMBO journal.
[16] S. Akira,et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release , 2010, Proceedings of the National Academy of Sciences.
[17] M. Humbert,et al. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.
[18] E. Aronica,et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures , 2010, Nature Medicine.
[19] M. Andrassy,et al. The Role of HMGB1/RAGE in Inflammatory Cardiomyopathy , 2010, Seminars in thrombosis and hemostasis.
[20] Carsten Ehrhardt,et al. The Receptor for Advanced Glycation End Products (RAGE) and the Lung , 2010, Journal of biomedicine & biotechnology.
[21] D. Hackam,et al. Toll-like receptor-4 inhibits enterocyte proliferation via impaired beta-catenin signaling in necrotizing enterocolitis. , 2010, Gastroenterology.
[22] R. Rieben,et al. TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells. , 2009, Molecular immunology.
[23] M. Maitland,et al. Inflammation, growth factors, and pulmonary vascular remodeling. , 2009, Journal of the American College of Cardiology.
[24] P. Thistlethwaite,et al. Development and pathology of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.
[25] E. Mark,et al. Interleukin-6 Overexpression Induces Pulmonary Hypertension , 2009, Circulation research.
[26] S. Eddahibi,et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice , 2009, Respiratory research.
[27] A. Branzi,et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension , 2008, European heart journal.
[28] M. Wilkins,et al. Emerging concepts and translational priorities in pulmonary arterial hypertension. , 2008, Circulation.
[29] Merlin C. Thomas,et al. Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. , 2008, American journal of physiology. Endocrinology and metabolism.
[30] T. Billiar,et al. HMGB1: Endogenous Danger Signaling , 2008, Molecular medicine.
[31] M. Cinelli,et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension , 2007, Annals of the rheumatic diseases.
[32] M. Rabinovitch. Molecular pathogenesis of pulmonary arterial hypertension. , 2008, The Journal of clinical investigation.
[33] K. Tracey,et al. Systemic inflammation and remote organ injury following trauma require HMGB1. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.
[34] L. Tavazzi,et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. , 2007, American heart journal.
[35] R. Tuder,et al. Pathology of pulmonary hypertension. , 2007, Clinics in chest medicine.
[36] M. Rabinovitch. Pathobiology of pulmonary hypertension. , 2007, Annual review of pathology.
[37] M. Bianchi. DAMPs, PAMPs and alarmins: all we need to know about danger , 2007, Journal of leukocyte biology.
[38] E. Abraham,et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. , 2006, American journal of physiology. Cell physiology.
[39] R. Folz,et al. Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). , 2006, American journal of physiology. Lung cellular and molecular physiology.
[40] P. Kubes,et al. Platelets express functional Toll-like receptor-4. , 2005, Blood.
[41] K. Tracey,et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion , 2005, The Journal of experimental medicine.
[42] M. Humbert,et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[43] E. Schleicher,et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. , 2004, The Journal of clinical investigation.
[44] E. Abraham,et al. Involvement of Toll-like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein* , 2004, Journal of Biological Chemistry.
[45] W. Seeger,et al. Clinical classification of pulmonary hypertension. , 2001, Clinics in chest medicine.
[46] K. Tracey,et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[47] M. Lotze,et al. Dealing with death: HMGB1 as a novel target for cancer therapy. , 2003, Current opinion in investigational drugs.
[48] G. Längst,et al. The DNA chaperone HMGB1 facilitates ACF/CHRAC‐dependent nucleosome sliding , 2002, The EMBO journal.
[49] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[50] T. Minamino,et al. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[51] F. Katsuoka,et al. Type II alveolar epithelial cells in lung express receptor for advanced glycation end products (RAGE) gene. , 1997, Biochemical and biophysical research communications.
[52] J. Chen,et al. The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.
[53] B. Groves,et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.
[54] P. Matzinger. Tolerance, danger, and the extended family. , 1994, Annual review of immunology.
[55] D. Stewart,et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.
[56] B. Munt,et al. Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy. , 1992, The Journal of rheumatology.
[57] D. Friedman,et al. Recovery from pulmonary hypertension in an adolescent with mixed connective tissue disease. , 1992, Annals of the rheumatic diseases.